ACCENTIA BIOPHARMACEUTICALS INC (ABPI) [Rocket]

In millions, except per share items	Dec-31-12	Sep-30-12	Jun-30-12	Mar-31-12	Dec-31-11	Sep-30-11	Jun-30-11	Mar-31-11
	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues:
Products	412.1	848.5	848.6	848.5	848.4	2.4	2.7	3.4
Services	139.8	217.7	217.7	218.0	218.1	1.3
Other					169.3
Total revenues [+]	551.8	1,235.6	1,235.6	1,235.8	1,235.8	4.0	0.3	1.7
Products			1.7	1.7
Services			0.4	0.6
Revenue growth [+]	-55.3%	31133.1%	461809.5%	72822.8%	47757.9%	-26.1%	-97.3%	-83.7%
Products	-51.4%	35798.9%	30912.5%	25222.2%	23805.4%	-43.2%	-29.1%	10.2%
Services	-35.9%	17009.8%
Cost of goods sold [+]	583.2	642.7	642.2	642.1	642.0	3.0	-3.6	-2.6
Cost of product sales			1.0	0.9
Cost of services			0.5	0.5
Gross profit	-31.3	592.9	593.4	593.7	593.8	1.0	3.8	4.3
Gross margin	-5.7%	48.0%	48.0%	48.0%	48.1%	25.3%	1438.0%	252.0%
Selling, general and administrative [+]	971.7	999.5	999.9	1,001.7	1,001.4	20.7	18.8	17.1
Sales and marketing	26.3	27.2	27.2	27.2	27.2	0.1	0.1	0.1
General and administrative [+]	972.3	1,009.2	1,009.2	1,011.1	1,010.8	20.2	19.1	17.3
General and administrative expenses			5.1	7.0
Professional fees		-0.1	-0.4	-0.4		-0.7
Other selling, general and administrative	-26.9	-36.8			-36.5	0.4
Research and development	903.9	965.9	965.5	965.0	963.6	2.2	1.4	1.0
Other operating expenses	22.1	32.1		36.0	36.0	-0.9	3.5	3.5
EBITDA [+]	-2,013.8	-1,404.4	-1,407.5	-1,408.6	-1,277.8	-20.5	-19.3	-16.7
EBITDA growth	57.6%	6759.5%	7179.2%	8337.9%	8945.9%	682.2%	351.7%	253.6%
EBITDA margin	-364.9%	-113.7%	-113.9%	-114.0%	-103.4%	-517.5%	-7228.3%	-985.1%
Depreciation	-84.9	0.1	-0.1	0.0	33.1	0.0	0.1	0.1
EBITA	-1,928.9	-1,404.5	-1,407.4	-1,408.6	-1,310.9	-20.5	-19.4	-16.8
EBITA margin	-349.6%	-113.7%	-113.9%	-114.0%	-106.1%	-517.2%	-7264.4%	-992.5%
Amortization of intangibles	0.1	0.1	0.5	0.5	96.3	0.6	0.5	0.5
EBIT [+]	-1,929.0	-1,404.6	-1,407.9	-1,409.0	-1,407.2	-21.0	-19.9	-17.3
EBIT growth	37.1%	6577.5%	6977.9%	8036.6%	9430.3%	555.4%	314.1%	238.6%
EBIT margin	-349.6%	-113.7%	-113.9%	-114.0%	-113.9%	-531.7%	-7435.9%	-1021.9%
Non-recurring items		3.8				0.1	0.0	0.0
Interest expense	7,571.4	1,957.7	1,957.3	1,957.3	1,957.4	8.1	20.1	19.9
Interest expense	7,571.4	1,957.7	1,957.3	1,957.3	1,957.4	8.1	20.1	19.9
Other income (expense), net [+]	753.0	4,008.9	4,004.7	3,999.8	4,005.6	2.0	-19.7	-8.2
Reorganization items			5.4	1.0
Gain (loss) on debt retirement			5.5	1.0
Other			0.0	0.0		0.0
Pre-tax income	-8,751.3	642.8	639.4	633.4	640.8	-27.3	-59.7	-45.4
Income taxes	0.4	-439.4	-440.0	-439.7	-439.7	-7.6	-7.6	-7.6
Tax rate	0.0%			-69.4%		27.7%		16.8%
Minority interest		8.0	7.3	7.4		7.5	3.4	2.0
Earnings from continuing ops	-8,741.0	653.1	645.8	639.9	645.1	-20.4	-57.0	-43.9
Earnings from discontinued ops							-0.1
Net income	-8,741.0	653.1	645.8	639.9	645.1	-20.4	-57.1	-43.9
Net margin	-1584.0%	52.9%	52.3%	51.8%	52.2%	-515.9%	-21333.2%	-2589.8%

Basic EPS [+]	($144.61)	$10.80	$11.26	$11.80	$12.44	($0.30)	($1.13)	($0.93)
Growth	-1262.2%	-3678.7%	-1093.2%	-1370.8%	-522.2%	-95.0%	-62.9%
Diluted EPS [+]	($124.89)	$9.33	$9.65	$11.80	$12.44	($0.30)	($1.13)	($0.93)
Growth	-1103.7%	-3190.7%	-951.6%	-1370.8%	-522.2%	-95.0%	-62.9%

Shares outstanding (basic) [+]	60.4	60.4	57.4	54.2		67.4	50.3	47.3
Growth	16.6%	-10.3%	14.1%	14.7%		364.5%	246.6%
Shares outstanding (diluted) [+]	70.0	70.0	66.9	54.2		67.4	50.3	47.3
Growth	35.0%	3.8%	33.0%	14.7%		364.5%	246.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.